loading page

Prognostic Significance of Monocyte to High-density Lipoprotein Ratio in Patients With Coronary Chronic Total Occlusion
  • +2
  • Muhammed Demir,
  • Mehmet Ozbek,
  • Tuncay Güzel,
  • Adem Aktan,
  • Burhan Aslan
Muhammed Demir
Dicle University Medical Faculty
Author Profile
Mehmet Ozbek
Dicle University Medical Faculty
Author Profile
Tuncay Güzel
Diyarbakir Gazi Yasargil Training and Research Hospital
Author Profile
Adem Aktan
Mardin State Hospital
Author Profile
Burhan Aslan
Diyarbakir Gazi Yasargil Training and Research Hospital
Author Profile

Abstract

Objective: Development of chronic total occlusion (CTO) consists of multiple histological stages, with each stage containing different histopathological features. The monocyte to high-density lipoprotein ratio (MHR) is a useful marker of the degree of inflammatory response. The aim of this study was to investigate the relationship between MHR and long-term survival and mortality in CTO patients. Methods: The study included 493 CTO patients that were followed over a period of 73 months between January 2011 and December 2019. MHR was calculated from the venous blood samples taken from each patient immediately before routine coronary angiography. Results: The study included 493 patients comprising 353 (71.6%) men and 140 (28.4%) women with a mean age of 63.03±10.88 years. Median follow-up period was 48 (interquartile range [IQR]: 26-73) months. Patients were divided into two groups: (I) MHR <17.68 (n=278) and (II) MHR ≥17.68 (n=215). Long-term mortality was significantly higher in group II than in group I (n=70, 32.6% vs. n=43, 15.5%; p<0,001). On multivariate logistic regression analysis, MHR was found to be an independent predictor of long-term mortality (Odds Ratio [OR]: 1.089, 95% Confidence Interval [CI]: 1.055-1.124, p<0,001). The Kaplan-Meier analysis showed lower survival rates in group II (MHR ≥17.68) than in group I (MHR <17.68) (75.223±2.670 vs. 89.220±2.102, p<0,001). Conclusion: MHR could be used as a practical universal biomarker of mortality and survival in CTO patients.